Intuitive Surgical Stock Is Having Its Worst Year Since 2008. What's Behind the Sell-Off?
Intuitive Surgical (ISRG) stock has fallen 30% in 2026, its worst year since 2008. Q2 revenue grew 19%, but guidance was below expectations. Competition from Johnson & Johnson and Medtronic raises concerns. ISRG trades at 45x trailing earnings, higher than the S&P 500 average.
How this was made
The 30-second read
Why it matters
The article attributes the worst-year sell-off to investors reacting to full-year procedure growth guidance (13.5% to 15.5%) and to concerns that new competitive systems could erode market share, while valuation remains elevated.
Market read
Traders get a narrative link between ISRG’s guidance range, competitive clearance news, and valuation compression risk, but no new primary disclosure is introduced in the text.
What to watch
The piece does not quantify share loss, procedure mix, reimbursement changes, or whether guidance conservatism reflects timing of new installations, which could limit how far the multiple compresses.
Background
ISRG is a leading robotic-assisted surgery platform provider, with da Vinci procedures and a history of high valuation.
Ticker impact
Article cites ISRG Q2 guidance projecting da Vinci procedure growth of 13.5% to 15.5%, which investors found unimpressive.
Choppy to bearish near term, with potential stabilization only if subsequent updates re-accelerate procedure growth or valuation compresses.
The text’s newest concrete facts are the full-year procedure growth range and the competitive/regulatory read-across (J&J Ottava, Medtronic Hugo) that could pressure market share, both supporting a negative risk skew.
Market effects
Highlights competitive pressure in robotic-assisted surgery from cleared systems (J&J Ottava, Medtronic Hugo), which can reset expectations for the category’s growth durability.
No specific regional catalyst described.
Competition and regulatory clearances are presented as global read-through risks for medtech robotics demand and pricing power.
Counterpoint
Even with competition, the article argues ISRG has a “massive head start” and the robotic-assisted surgery market still offers room to grow, so the sell-off may be valuation-driven rather than fundamental collapse.
Key entities
- companyIntuitive Surgical
Subject of the article; guidance and valuation are cited as drivers of the sell-off.
- companyJohnson & Johnson
Mentioned as having regulatory clearance for its Ottava robotic surgical system, used as a competitive read-across.
- companyMedtronic
Mentioned as having regulatory clearance for its Hugo robotic-assisted surgery system, used as a competitive read-across.
